 |
104 Diseases |  |
139 Trials |
|
139 Trials |  |
6449 News |  |
| «12345678910111213...9091» |
- | Mekinist (trametinib) / Novartis, BeiGene, Zelboraf (vemurafenib) / Roche
Journal: ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling. (Pubmed Central) - May 19, 2024
Consistently, pharmacological inhibition of ALDH1A1 activity downregulated the activation of AKT and partially recovered responsiveness to vemurafenib and trametinib. We propose ALDH1A1 as a new potential target for treating melanoma resistant to MAPK/ERK inhibitors.
- || Mekinist (trametinib) / Novartis, BeiGene
Review, Journal: Small molecule inhibition for RASopathy-associated hypertrophic cardiomyopathy: Clinical application of a basic concept. (Pubmed Central) - May 16, 2024
We describe how drug repurposing of trametinib (MEK inhibiton) and sirolimus/everolimus (mTOR inhibition) was performed, how genotype-specific therapies are chosen and followed, as well as initial outcomes from early case series. Finally, we lay out the challenges and opportunities for trials that aim to quantify the benefits of this approach.
- | miransertib (MK-7075) / Merck (MSD), Ibrance (palbociclib) / Pfizer, Nerlynx (neratinib) / Puma
Journal, Combination therapy: Synergistic Effects of Neratinib in Combination With Palbociclib or Miransertib in Brain Cancer Cells. (Pubmed Central) - May 16, 2024
Notably, we found that treatment with neratinib in combination with palbociclib (CDK4/6 inhibitor), or miransertib (AKT1/2/3 inhibitor) resulted in synergistic growth inhibition of all HBCCLs. Our results support that repurposing drugs like neratinib in combination with the palbociclib or miransertib may be of therapeutic potential in brain cancer and warrants further investigations.
- | Preclinical, Journal, Tumor microenvironment, Immune cell: A zebrafish xenotransplant model of anaplastic thyroid cancer to study the tumor microenvironment and innate immune cell interactions in vivo. (Pubmed Central) - May 15, 2024
Lastly, we tested two drug treatments, AZD2014 and a combination therapy of dabrafenib and trametinib to show our model could be used as an effective screening platform for new therapeutic compounds for ATC. Altogether, we show that zebrafish xenotransplants make a great model to study thyroid carcinogenesis and the tumor microenvironment, while also being a suitable model to test new therapeutics in vivo.
- | Mekinist (trametinib) / Novartis, BeiGene
Journal, PD(L)-1 Biomarker, IO biomarker: D-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity. (Pubmed Central) - May 15, 2024
Furthermore, D-mannose treatment dramatically improves the therapeutic efficacy of MEK inhibitor (MEKi) trametinib in vivo. Our findings unveil a universally unrecognized anti-tumor mechanism of D-mannose by destabilizing PD-1 and provide strategies to enhance the efficacy of both immune checkpoint blockade (ICB) and MEKi -based therapies.
- | Mekinist (trametinib) / Novartis, BeiGene, Tagrisso (osimertinib) / AstraZeneca, Xpovio (selinexor) / Karyopharm, FORUS Therap
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker: HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer. (Pubmed Central) - May 14, 2024
Selinexor with a PD-1 inhibitor with or without trametinib abrogates the tumor growth in the murine Lewis lung cancer model. An in-depth exploration of the functions of HMGB1 mRNA and protein is expected to uncover new potential targets and provide a basis for treating metastatic NSCLC in combination with ICI.
- ||||||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Trial completion, Trial completion date, Trial primary completion date, HEOR, Metastases: OCEANMIST: Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (clinicaltrials.gov) - May 13, 2024
P=N/A, N=1, Completed, Sponsor: Pfizer
An in-depth exploration of the functions of HMGB1 mRNA and protein is expected to uncover new potential targets and provide a basis for treating metastatic NSCLC in combination with ICI. Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Dec 2023 | Trial primary completion date: Jul 2024 --> Dec 2023
- | naporafenib (ERAS-254) / Erasca
Trial completion date, Metastases: Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (clinicaltrials.gov) - May 13, 2024
P2, N=134, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Dec 2023 | Trial primary completion date: Jul 2024 --> Dec 2023 Trial completion date: Apr 2024 --> Jul 2024
- | Mekinist (trametinib) / Novartis, BeiGene
Preclinical, Journal: Trametinib inhibits lymphatic vessel invasion of bone in a mouse model of Gorham-Stout disease. (Pubmed Central) - May 13, 2024
Our results show trametinib impacts bone disease in Osx-tTA;TetO-Vegfc mice. These findings further support the testing of MEK inhibitors in patients with GSD and other RAS pathway-driven complex lymphatic anomalies with bone involvement.
- | Journal: Dabrafenib and trametinib-BRAF V600E mutated pediatric gliomas (Pubmed Central) - May 11, 2024
These findings further support the testing of MEK inhibitors in patients with GSD and other RAS pathway-driven complex lymphatic anomalies with bone involvement. No abstract available
- || Review, Journal: RAF and MEK Inhibitors in Non-Small Cell Lung Cancer. (Pubmed Central) - May 11, 2024
New RAF and MEK inhibitors, with distinct biochemical characteristics, are in preclinical and clinical development. In this review, we aim to provide valuable insights into the current state of RAF and MEK inhibition in the management of NSCLC, fostering a deeper understanding of the potential impact on patient outcomes.
- | Mekinist (trametinib) / Novartis, BeiGene, Rozlytrek (entrectinib) / Roche
Preclinical, Journal: Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model. (Pubmed Central) - May 9, 2024
In this review, we aim to provide valuable insights into the current state of RAF and MEK inhibition in the management of NSCLC, fostering a deeper understanding of the potential impact on patient outcomes. Drug synergy was seen using trametinib and rapamycin in combination with entrectinib.
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Retrospective data, Journal: Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors. (Pubmed Central) - May 8, 2024
BRAF-mutated NEC is sensitive to treatment with BRAF- and MEK-inhibitor combination. These results further support that DNA sequencing should be considered as standard of care in NECs to screen for potential treatment targets.
- ||| Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis
Trial completion date, Trial primary completion date, Metastases: Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (clinicaltrials.gov) - May 7, 2024
P3, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
These results further support that DNA sequencing should be considered as standard of care in NECs to screen for potential treatment targets. Trial completion date: Aug 2024 --> Jun 2027 | Trial primary completion date: Jul 2024 --> May 2027
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Journal, Real-world evidence, Real-world: Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience. (Pubmed Central) - May 6, 2024
The combination was well tolerated. We confirm the efficacy of dabrafenib/trametinib in BRAF-V600-mutated NSCLC.
- ||| CFT1946 / C4 Therap
Enrollment change, Combination therapy, Monotherapy: A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors (clinicaltrials.gov) - May 2, 2024
P1/2, N=206, Recruiting, Sponsor: C4 Therapeutics, Inc.
We confirm the efficacy of dabrafenib/trametinib in BRAF-V600-mutated NSCLC. N=102 --> 206
- |||||| naporafenib (ERAS-254) / Erasca
Enrollment open, Monotherapy, Metastases: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) (clinicaltrials.gov) - May 1, 2024
P3, N=470, Recruiting, Sponsor: Erasca, Inc.
N=102 --> 206 Not yet recruiting --> Recruiting
- | Amtagvi (lifileucel) / Iovance Biotherap
Journal: Lifileucel (Amtagvi): A cellular therapy for melanoma. (Pubmed Central) - May 1, 2024
Not yet recruiting --> Recruiting No abstract available
- | Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
Trial completion date: Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (clinicaltrials.gov) - Apr 30, 2024
P1, N=27, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
No abstract available Trial completion date: Mar 2024 --> Aug 2024
- || Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
P1 data, Journal: A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. (Pubmed Central) - Apr 29, 2024
P1/2
Trial completion date: Mar 2024 --> Aug 2024 Concomitant inhibition of both the MAPK and PI3K-AKT pathways for the treatment of BRAF-mutated cancers was well tolerated, leading to objective responses, but higher level drug-drug interactions affected exposure to dabrafenib and its metabolites.
- Mekinist (trametinib) / Novartis, BeiGene
Trametinib-induced acneiform eruption (e-Poster Hall) - Apr 28, 2024 - Abstract #EADVSp2024EADV_Sp_51;
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Journal: Characterization of BRAFThr599dup Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling. (Pubmed Central) - Apr 25, 2024
BRAFThr599dup is a potent driver oncogene that activates the MAPK pathway without the requirement for dimerization in vitro. Because BRAFThr599dup has been recurrently reported across various cancer types, our findings should be further investigated both mechanistically and clinically.
- | Mekinist (trametinib) / Novartis, BeiGene
Journal: NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer. (Pubmed Central) - Apr 25, 2024
Because BRAFThr599dup has been recurrently reported across various cancer types, our findings should be further investigated both mechanistically and clinically. Our study comprehensively analyzed metabolic gene expression and highlighted the importance of NOX4 in promoting CRC metastasis, suggesting that trametinib could be a potential therapeutic drugs of CRC clinical therapy targeting NOX4.
- || Lumakras (sotorasib) / Amgen
Trial primary completion date, Monotherapy, Metastases: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Apr 25, 2024
P1/2, N=1126, Recruiting, Sponsor: Amgen
Our study comprehensively analyzed metabolic gene expression and highlighted the importance of NOX4 in promoting CRC metastasis, suggesting that trametinib could be a potential therapeutic drugs of CRC clinical therapy targeting NOX4. Trial primary completion date: Sep 2026 --> Dec 2026
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6751;
P2
High ORR was seen with PD-L1 TPS ?50. Survival outcomes and genomic biomarkers, currently under investigation, will be presented at the meeting.
- Utilizing stereotactic body radiation therapy in combination with tyrosine kinase inhibitors for therapeutic benefit in thyroid cancer. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6711;
SBRT can be effectively and safely administered to achieve durable disease control in patients with aggressive thyroid cancer histology when combined with tyrosine kinase inhibitors. This strategy warrants evaluation in prospective clinical trials.
- Mekinist (trametinib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tafinlar (dabrafenib) / Novartis, BeiGene
A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5726;
It's worth noticing that immune activation occurred in responsive patients, indicated a potential benefit from immunotherapy combination therapy. Moreover, Hedgehog signaling pathway may be target in rescue therapy in mCRC patients.
- Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_5689;
P1/2
A significant proportion received subsequent lines of therapy post ICI, and exploration of ORR and PFS to next lines of therapy is of interest. Clinical trial information: NCT02538510 and NCT03749460.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
CD44 and CD271 expression and chemoresistance in BRAF V600E/K mutation () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4974;
Clinical trial information: NCT02538510 and NCT03749460. 25
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4947;
P=N/A
Prognostic groups could help in the selection of patients who could achieve a complete response, since it is the most important prognostic biomarker. Clinical trial information: NCT03605771.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Options for enhancing specific antitumor immunity in patients with melanoma. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4942;
Determination of TREC levels during adjuvant therapy demonstrated the effectiveness of dabrafenib in combination with trametinib and interferon ?-2?, which is reflected in a significant increase in the T-cell receptor repertoire. The presented data indicate the possibility of using the method for determining the TREC level to predict the risk of cancer progression and the effectiveness of prescribed therapy.
- Mekinist (trametinib) / Novartis, BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Tafinlar (dabrafenib) / Novartis, BeiGene
Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4928;
P2
Our findings highlights factors that modify the TME towards immune suppression, tumor programs resistance, MAPK up-regulation and can thus enhance drug resistance. Clinical trial information: NCT03149029.
- Utilization and trends of BRAF and MEK inhibitors among Medicare D patients: 2013-2021. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_4339;
BRAF/MEK Inhibitor use has seen significant growth across all healthcare providers in claims made per 100k beneficiaries, total drug costs, and total drug supply days. These findings show that the access to BRAK/MEK inhibitor is increasing and as it receives indications for other malignancies, additional studies will be needed to assess whether these trends persist or change, especially in setting of increased use of immunotherapy in melanoma.
- A multicohort platform trial to improve drug access for pediatric cancer patients in Japan: The PARTNER trial (NCCH2220). (Hall A; Poster Bd #: 445a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3449;
We started planning the study in November 2022, and enrollment began on January 18, 2024. This platform trial has enabled us to deliver drugs to patients more quickly and efficiently than by conducting individual early-phase trials for each drug.
- Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. (Hall B1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3243;
P3
NADINA is the first phase 3 trial that evaluates neoadj immunotherapy against SOC in melanoma, and is also the first phase 3 trial in oncology evaluating a neoadj regimen consisting of immunotherapy alone. Neoadj IPI+NIVO followed by response-driven adj treatment results in statistically significant improved EFS compared to adj NIVO and should be considered a new SOC treatment in macroscopic stage III melanoma.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study. (Hall A; Poster Bd #: 354) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3161;
P2
While clinical outcomes using Dab-Tram as first line therapy for BRAFV600E PLGG are promising, our model-based analysis demonstrates that at the present price, Dab-Tram is not cost-effective, and would require a considerable price reduction to enable equitable access and affordability. This work also provides an exemplar for economic evaluation of precision therapies based on emergent trial and real-world data for rare diseases.
- Mekinist (trametinib) / Novartis, BeiGene, naporafenib (ERAS-254) / Erasca
An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1). (Hall A; Poster Bd #: 314a) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2149;
P1
A total of up to 115 pts will be enrolled to receive naporafenib 200 mg BID and trametinib 1 mg QD continuous in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint is ORR; secondary endpoints include assessment of PFS, DOR, safety, and tolerability.
- PAS-004 / Pasithea
PAS-004: A novel macrocyclic MEK inhibitor to inhibit cancer cell growth in vitro and tumor growth in mouse xenograft studies. (Hall A; Poster Bd #: 271) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2097;
In vitro, PAS-004 provided greater maximal growth inhibition of NRAS lines than selu and bini. These results support investigating PAS-004 further and a clinical trial in patients with advanced solid tumors carrying RAS pathway mutations, including NRAS variants, is ongoing.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Targeting rare variants of a pan-cancer target: The landscape of BRAF non-v600 mutations and BRAF fusions from 172,005 adult patients with cancer. (Hall A; Poster Bd #: 258) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2085;
Atypical non-V600 BRAFalterations and BRAF fusions represent a distinct molecular cohort across cancers. Most BRAF fusion events and non-V600 missense mutations are characterized as oncogenic, underlining the spectrum of BRAF inhibition, and the urgent need to expand agents beyond the current BRAFV600 indications.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H. (Hall A; Poster Bd #: 255) - Apr 24, 2024 - Abstract #ASCO2024ASCO_2082;
P2
1. J Clin Oncol.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Response to targeted and immune therapy in patients with NSCLC and BRAF non-V600E mutations: A retrospective, multicenter analysis within the national Network Genomic Medicine Lung Cancer (nNGM) in Germany. (Hall A; Poster Bd #: 455) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1466;
Hence, it is of key importance to apply preclinical activation assays showing good correlations to clinical outcomes in our study prior to applying targeted therapy in patients with unknown BRAF non-V600E mutations. Altogether, our study helps to guide personalized treatment decisions in this patient population.
- Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy. (Hall A; Poster Bd #: 406) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1418;
P1
Altogether, our study helps to guide personalized treatment decisions in this patient population. This study provides a potential combinational therapeutic strategy for those non-G12C KRAS-mutant lung cancer patients via oral administration of trametinib and anlotinib.
- Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study. (Hall D1) - Apr 24, 2024 - Abstract #ASCO2024ASCO_816;
P3
OS was improved with dabrafenib plus trametinib over placebo for adjuvant treatment of stage III melanoma with a 20% risk reduction for death. However, this difference was not statistically significant.
- | Mekinist (trametinib) / Novartis, BeiGene
Preclinical, Journal: Therapeutic efficacy of RAS inhibitor trametinib using a juvenile myelomonocytic leukemia patient-derived xenograft model. (Pubmed Central) - Apr 22, 2024
In conclusion, trametinib monotherapy significantly prolongs survival in our JMML PDX model by inhibiting the RAS pathway. Our model can be effectively used for assessment of novel targeted treatments, including potential combination therapies, to improve JMML outcomes.
- | Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial completion, Trial completion date, Trial primary completion date: Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients (clinicaltrials.gov) - Apr 22, 2024
P1, N=33, Completed, Sponsor: Shanghai Chest Hospital
Our model can be effectively used for assessment of novel targeted treatments, including potential combination therapies, to improve JMML outcomes. Recruiting --> Completed | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Jul 2023
- | Trial completion date, Trial primary completion date, Metastases: DREAMseq: Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (clinicaltrials.gov) - Apr 18, 2024
P3, N=300, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Jul 2023 Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- || Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Review, Journal, Tumor mutational burden, BRCA Biomarker, PD(L)-1 Biomarker, IO biomarker: Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution. (Pubmed Central) - Apr 17, 2024
The existing format of data dissemination may not be optimal for agnostic cancer medicine, as conventional scientific journals are understandably biased towards the publication of positive findings and usually discourage the submission of case reports. Despite all the limitations and concerns, histology-independent drug-target matching is certainly feasible and, therefore, will be increasingly utilized in the future.
- || BI 1701963 / Boehringer Ingelheim
Trial primary completion date, Combination therapy, Monotherapy, Metastases: A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (clinicaltrials.gov) - Apr 16, 2024
P1, N=71, Active, not recruiting, Sponsor: Boehringer Ingelheim
Despite all the limitations and concerns, histology-independent drug-target matching is certainly feasible and, therefore, will be increasingly utilized in the future. Trial primary completion date: Mar 2024 --> Oct 2024
- || Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
Enrollment change, Trial completion date, Trial primary completion date: A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 16, 2024
P1, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Trial primary completion date: Mar 2024 --> Oct 2024 N=60 --> 30 | Trial completion date: Sep 2022 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2024
- | Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, BeiGene
New P2 trial: Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy (clinicaltrials.gov) - Apr 11, 2024
P2, N=10, Recruiting, Sponsor: Saint Petersburg State University, Russia